COST-EFFECTIVENESS OF OMALIZUMAB FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN FRANCE
Author(s)
Cariou C, Duteil E, Benjamin K, Duco J
Novartis Pharma, Rueil-Malmaison, France
Presentation Documents
OBJECTIVES:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PSS36
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Sensory System Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now